Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Tenaya Therapeutics $75 million at-the-market offering
The common stock is listed on the Nasdaq Global Select Market
ADC Therapeutics $175 million term loan facility and other financings
We advised the company on the new facility, a $115 million exchange and a $6.25 million share sale
Terns Pharmaceuticals $65 million common stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
InSilico Medicine $35 million Series D2 financing
We are advising InSilico Medicine on the financing
Vaccitech $75 million at-the-market offering
The ADSs are listed on the Nasdaq Global Market
RxSight $50 million at-the-market offering
The stock is listed on the Nasdaq Global Market
TransMedics Group $150 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Gilead Sciences $405 million acquisition of MiroBio
We are advising Gilead Sciences on the transaction
Allakos $75 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Taibang Biologic Group $300 million equity raising
We are advising Taibang Biologic Group in connection with its equity raising by a group of investors